AstraZeneca treatment for hypereosinophilic syndrome granted orphan status

Writer, Stock Market Wire
Wednesday, February 6, 2019 - 08:19

AstraZeneca said US regulators had granted orphan drug status for its treatment for hypereosinophilic syndrome, a rare condition that can damage organs in the body.

The Food and Drug Administration grants orphan status to medicines intended for the treatment of rare diseases or disorders that affect fewer than 200,000 people in the US.

A phase II clinical trial of the treatment, Fasenra, had been conducted by the US National Institutes of Health in collaboration with AstraZeneca.

The results were expected to be published later in 2019.

At 8:19am: (LON:AZN) AstraZeneca PLC share price was -46p at 5663p

Related content

AstraZeneca buys US Food and Drug Administration priority review voucher for $95m

AstraZeneca said it had agreed to buy a US Food and Drug Administration priority review voucher for $95m in cash from a subsidiary of Swedish...

Thu, 22/08/2019 - 07:32

AstraZeneca's anaemia treatment given regulatory nod in China

AstraZeneca said its drug to treat anaemia in non-dialysis-dependent patients suffering from chronic kidney disease had received marketing authorisation in China.

'With this approval for...

Thu, 22/08/2019 - 07:31

AstraZeneca combination lung cancer treatment fails to meet primary goal

AstraZeneca said a clinical trial of its lung cancer treatment failed to meet its primary goal of improving survival rates compared with chemotherapy.


Wed, 21/08/2019 - 07:26

Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7800p (from 7600p).

Broker Forecasts data provided...

Fri, 16/08/2019 - 08:30

The DNA of the FTSE 350


If you are new to stock market investing you may still have heard of the FTSE 100. It frequently appears on TV news bulletins and...

Thu, 15/08/2019 - 00:00